{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:30:09Z","timestamp":1790562609158,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006304","name":"Aalborg University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006304","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with hypothalamic pathology often develop hypothalamic obesity, causing severe metabolic alterations resulting in increased morbidity and mortality. Treatments for hypothalamic obesity have not proven very effective, although the glucagon-like peptide-1 receptor agonist semaglutide has been shown to have positive effects. We examined semaglutide\u2019s effect on weight loss in a sample of patients with hypothalamic obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four female patients with hypothalamic obesity resulting from treatment of craniopharyngiomas were treated with semaglutide for six months. Whole Body Dual-energy x-ray absorptiometry scans were performed, and blood samples drawn at baseline and after six months. Semaglutide dosages were increased monthly along with tracking of body weight and eating behavior (Three Factor Eating Questionnaire, TFEQ-R18).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BMI was reduced in all cases, with an average of 7.9 BMI (range: 6.7 to 10.1) corresponding to a weight loss of 17.0% (range: 11.3\u201322.4%) or 20.2\u00a0kg (range 16.2\u00a0kg to 23.4\u00a0kg). We found a comparable reduction in total fat mass (17.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) and lean mass (16.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05), whereas bone mass was unchanged (2.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12). All cases reported an increase in energy levels, improved mobility and physical activity. Unfavorable eating behaviors were reduced after 1 month of treatment (emotional eating \u2212\u200941 points,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02, uncontrolled eating \u2212\u200923 points,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.11). HbA1c and total cholesterol were significantly reduced (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014 for both).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide is a promising and safe treatment option for HO, that improves eating behavior, reduces weight, and improves metabolic markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-024-01426-8","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T03:07:36Z","timestamp":1722481656000},"page":"723-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1391-8009","authenticated-orcid":false,"given":"Erlend","family":"Gjersdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liva Bundgaard","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re Schmidt","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eigil Husted","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Scott","family":"Karmisholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann L.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"1","key":"1426_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","volume":"8","author":"HL M\u00fcller","year":"2022","unstructured":"M\u00fcller HL, Tauber M, Lawson EA et al (2022) Hypothalamic syndrome. Nat Rev Dis Primers 8(1):24","journal-title":"Nat Rev Dis Primers"},{"key":"1426_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fendo.2011.00049","volume":"2","author":"CL Roth","year":"2011","unstructured":"Roth CL (2011) Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits. Front Endocrinol 2:49","journal-title":"Front Endocrinol"},{"issue":"3","key":"1426_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ecl.2020.05.009","volume":"49","author":"HL M\u00fcller","year":"2020","unstructured":"M\u00fcller HL (2020) Management of hypothalamic obesity. Endocrinol Metab Clin North Am 49(3):533\u2013552","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"1426_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/er.2006-0002","volume":"27","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Cudlip S, Adams CBT, Wass JAH, Craniopharyngiomas (2006) Endocr Rev 27(4):371\u2013397","journal-title":"Endocr Rev"},{"key":"1426_CR5","doi-asserted-by":"publisher","unstructured":"Gatta-Cherifi B, Mohammedi K, Cariou T et al (2024) Impact of exenatide on weight loss and eating behaviour in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol Published Online March 7. https:\/\/doi.org\/10.1093\/ejendo\/lvae024","DOI":"10.1093\/ejendo\/lvae024"},{"issue":"8","key":"1426_CR6","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/dom.15113","volume":"25","author":"HJ Silver","year":"2023","unstructured":"Silver HJ, Olson D, Mayfield D et al (2023) Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab 25(8):2340\u20132350","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1426_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"key":"1426_CR8","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351","journal-title":"Mol Metab"},{"issue":"7","key":"1426_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/dom.14366","volume":"23","author":"FA Perez","year":"2021","unstructured":"Perez FA, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ, Roth CL (2021) MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity. Diabetes Obes Metab 23(7):1532\u20131541","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1426_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/dom.14224","volume":"23","author":"CL Roth","year":"2021","unstructured":"Roth CL, Perez FA, Whitlock KB et al (2021) A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab 23(2):363\u2013373","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1426_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/EJE-12-0997","volume":"168","author":"F Zoicas","year":"2013","unstructured":"Zoicas F, Droste M, Mayr B, Buchfelder M, Sch\u00f6fl C (2013) GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol 168(5):699\u2013706","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 2","key":"1426_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.15530","volume":"26","author":"CL Roth","year":"2024","unstructured":"Roth CL, McCormack SE (2024) Acquired hypothalamic obesity: a clinical overview and update. Diabetes Obes Metab 26(Suppl 2):34\u201345","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1426_CR13","doi-asserted-by":"publisher","first-page":"luad074","DOI":"10.1210\/jcemcr\/luad074","volume":"1","author":"C Sciacovelli","year":"2023","unstructured":"Sciacovelli C, Moschione G, Garelli S, Pagotto U (2023) Semaglutide for treating obesity Induced by Craniopharyngioma Resection: a successful case study. JCEM Case Rep 1(4):luad074","journal-title":"JCEM Case Rep"},{"issue":"3","key":"1426_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21(3):201\u2013223","journal-title":"Nat Rev Drug Discov"},{"key":"1426_CR15","doi-asserted-by":"publisher","unstructured":"Gabery S, Salinas CG, Paulsen SJ et al (2020) Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5(6). https:\/\/doi.org\/10.1172\/jci.insight.133429","DOI":"10.1172\/jci.insight.133429"},{"issue":"12","key":"1426_CR16","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/sj.ijo.0801442","volume":"24","author":"J Karlsson","year":"2000","unstructured":"Karlsson J, Persson LO, Sj\u00f6str\u00f6m L, Sullivan M (2000) Psychometric properties and factor structure of the three-factor eating questionnaire (TFEQ) in obese men and women. Results from the Swedish obese subjects (SOS) study. Int J Obes Relat Metab Disord 24(12):1715\u20131725","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"9","key":"1426_CR17","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/jn\/134.9.2372","volume":"134","author":"B de Lauzon","year":"2004","unstructured":"de Lauzon B, Romon M, Deschamps V et al (2004) The three-factor eating Questionnaire-R18 is able to distinguish among different eating patterns in a general population. J Nutr 134(9):2372\u20132380","journal-title":"J Nutr"},{"issue":"6","key":"1426_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ijo.2009.74","volume":"33","author":"JC Cappelleri","year":"2009","unstructured":"Cappelleri JC, Bushmakin AG, Gerber RA et al (2009) Psychometric analysis of the three-factor eating Questionnaire-R21: results from a large diverse sample of obese and non-obese participants. Int J Obes 33(6):611\u2013620","journal-title":"Int J Obes"},{"issue":"2","key":"1426_CR19","first-page":"100","volume":"12","author":"SA Mostafavi","year":"2017","unstructured":"Mostafavi SA, Akhondzadeh S, Mohammadi MR et al (2017) The reliability and validity of the Persian Version of three-factor eating Questionnaire-R18 (TFEQ-R18) in overweight and obese females. Iran J Psychiatry 12(2):100\u2013108","journal-title":"Iran J Psychiatry"},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1479-5868-6-41","volume":"6","author":"S Angl\u00e9","year":"2009","unstructured":"Angl\u00e9 S, Engblom J, Eriksson T et al (2009) Three factor eating questionnaire-R18 as a measure of cognitive restraint, uncontrolled eating and emotional eating in a sample of young Finnish females. Int J Behav Nutr Phys Act 6:41","journal-title":"Int J Behav Nutr Phys Act"},{"key":"1426_CR21","first-page":"e12642","volume":"25","author":"VWW Ng","year":"2024","unstructured":"Ng VWW, Gerard G, Koh JJK, Loke KY, Lee YS, Ng NBH (2024) The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review. Clin Obes Published Online January 25:e12642","journal-title":"Clin Obes Published Online January"},{"issue":"6","key":"1426_CR22","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/oby.21493","volume":"24","author":"JP Lomenick","year":"2016","unstructured":"Lomenick JP, Buchowski MS, Shoemaker AH (2016) A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity 24(6):1222\u20131225","journal-title":"Obesity"},{"key":"1426_CR23","first-page":"1","volume":"18","author":"A Bikou","year":"2024","unstructured":"Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C (2024) A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. Published Online April 18:1\u20139","journal-title":"Published Online April"},{"issue":"1","key":"1426_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","volume":"25","author":"NC Bergmann","year":"2023","unstructured":"Bergmann NC, Davies MJ, Lingvay I, Knop FK (2023) Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab 25(1):18\u201335","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1426_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.6065\/apem.2013.18.4.161","volume":"18","author":"JH Kim","year":"2013","unstructured":"Kim JH, Choi JH (2013) Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents. Ann Pediatr Endocrinol Metab 18(4):161\u2013167","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"12","key":"1426_CR26","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1210\/jc.2010-0993","volume":"95","author":"H Holmer","year":"2010","unstructured":"Holmer H, Pozarek G, Wirf\u00e4lt E et al (2010) Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab 95(12):5395\u20135402","journal-title":"J Clin Endocrinol Metab"},{"key":"1426_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.appet.2017.04.023","volume":"116","author":"BL James","year":"2017","unstructured":"James BL, Loken E, Roe LS, Rolls BJ (2017) The weight-related eating questionnaire offers a concise alternative to the three-factor eating questionnaire for measuring eating behaviours related to weight loss. Appetite 116:108\u2013114","journal-title":"Appetite"},{"key":"1426_CR28","doi-asserted-by":"publisher","unstructured":"Leon AD, Roemmich J, Casperson S (2019) Responses on the three factor eating Questionnaire Restraint and Disinhibition scales Change after a Controlled Energy-Restricted Diet (P21-002-19). Curr Developments Nutr 3(Suppl 1). https:\/\/doi.org\/10.1093\/cdn\/nzz041.P21-002-19","DOI":"10.1093\/cdn\/nzz041.P21-002-19"},{"issue":"4","key":"1426_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000509302","volume":"13","author":"J van Schaik","year":"2020","unstructured":"van Schaik J, Begijn DGA, van Iersel L et al (2020) Experiences with Glucagon-Like Peptide-1 receptor agonist in children with acquired hypothalamic obesity. Obes Facts 13(4):361\u2013370","journal-title":"Obes Facts"},{"issue":"16","key":"1426_CR30","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2169\/internalmedicine.53.1646","volume":"53","author":"T Ando","year":"2014","unstructured":"Ando T, Haraguchi A, Matsunaga T et al (2014) Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity. Intern Med 53(16):1791\u20131795","journal-title":"Intern Med"},{"key":"1426_CR31","doi-asserted-by":"publisher","unstructured":"Botero Suarez CS, Broutin D, Yau H (2023) FRI064 the role of GLP-1 receptor agonists in the treatment of Pituitary and Hypothalamic Tumor Induced obesity. J Endocr Soc 7(Supplement1). https:\/\/doi.org\/10.1210\/jendso\/bvad114.074","DOI":"10.1210\/jendso\/bvad114.074"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01426-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T19:03:34Z","timestamp":1730747014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01426-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01426-8","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"3 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"E.G., L.B.L., E.H.N., J.S.K. and K.S.E. have no competing interests to declare that are relevant to the content of this article. P.V. is head of research at the Steno Diabetes Center North Denmark, funded by an unrestricted grant by the Novo Nordisk Foundation. H.L.M. has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Pfizer, Sandoz\/Hexal, Novo Nordisk, IPSEN, Rhythm Pharmaceuticals, and Merck Serono. He has also received reimbursement of travel expenses from Merck Serono, Rhythm Pharmaceuticals, and IPSEN and a lecture honoraria from Pfizer. J.D. has received unrestricted research grants from IPSEN and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}